ARTICLE | Discovery & Translation
AML gains new targets at ASH 2022
BioCentury identifies 29 novel drug targets at ASH 2022; 15 are proposed for AML
December 8, 2022 8:09 PM UTC
Acute myelogenous leukemia appears headed toward benefitting from advances in immune cell therapies and precision oncology, according to BioCentury’s analysis of new targets presented at ASH 2022.
Among the 29 new targets identified in this year’s American Society of Hematology (ASH) abstracts, more than half (15) are proposed as points of intervention for acute myelogenous leukemia (AML). ...